Search

Author/Creator Kazierad, David J.

1. A 4-week study assessing the pharmacokinetics, pharmacodynamics, safety, and tolerability of the glucagon receptor antagonist PF-06291874 administered as monotherapy in subjects with type 2 diabetes mellitus. (April 2017)

Authors:
Bergman, Arthur; Tan, Beesan; Somayaji, Veena R.; Calle, Roberto A.; Kazierad, David J.
Journal:
Diabetes research and clinical practice
Issue:
Volume 126(2017)
Page Start:
95
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Effect of Hepatic Organic Anion‐Transporting Polypeptide 1B Inhibition and Chronic Kidney Disease on the Pharmacokinetics of a Liver‐Targeted Glucokinase Activator: A Model‐Based Evaluation. Issue 4 (8th April 2019)

Authors:
Bergman, Arthur; Bi, Yi‐an; Mathialagan, Sumathy; Litchfield, John; Kazierad, David J.; Pfefferkorn, Jeffrey A.; Varma, Manthena V.S.
Journal:
Clinical pharmacology & therapeutics
Issue:
Volume 106:Issue 4(2019)
Page Start:
792
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Efficacy and safety of the glucagon receptor antagonist PF‐06291874: A 12‐week, randomized, dose‐response study in patients with type 2 diabetes mellitus on background metformin therapy. Issue 11 (30th July 2018)

Authors:
Kazierad, David J.; Chidsey, Kristin; Somayaji, Veena R.; Bergman, Arthur J.; Calle, Roberto A.
Journal:
Diabetes, obesity & metabolism
Issue:
Volume 20:Issue 11(2018)
Page Start:
2608
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗